Drugs / DC AML Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01096602 | May 2010 → Dec 2023 | acute myeloid leukemia | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC AML Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01096602 ↗ |
| Modality | Vaccine | “The DC AML vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells.” NCT01096602 ↗ |